Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer

Company Anticipates IND Filing In 2022-2023

 
• By Alaric DeArment

The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Senti Bio raises $105m in Series B round to develop chimeric antigen receptor natural killer cell therapies. • Source: Shutterstock

More from Anticancer

More from Therapy Areas